In Brief
Refine Search
Biotechnology
AstraZeneca on Monday announced the successful completion of an equity investment with France-based Cellectis, a clinical-stage biotechnology company. 6 May 2024
Pharmaceutical
Subsidies for Danish drugmaker giant Novo Nordisk’s diabetes drug Ozempic (semaglutide) will be restricted in its home country due to rising public spending on the blockbuster diabetes medicine, which is increasingly being used as a weight-loss treatment, according to a report from Bloomberg. 2 May 2024
Pharmaceutical
As of May 1, Johnson & Johnson is updating its brand and uniting both its two business segments under the Johnson & Johnson brand name in the UK. 1 May 2024
Generics
Danish specialty pharma company Xellia Pharmaceuticals, which is owned by Novo Holdings, today revealed that the US Court has vacated the Modified Consent Decree imposed on Xellia’s Cleveland, Ohio, USA facility in 2016. 29 April 2024
Pharmaceutical
US antivirals specialist Gilead Sciences announced that the US Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets, B/F/TAF) to treat pregnant people with HIV-1 (PWH) with suppressed viral loads. 27 April 2024
Biotechnology
CNS-focused biotech company Cerevance has announced an initial closing of its series B-1 extension financing round that will add $47 million to the $51 million previously raised, bringing the total series B-1 raise to $98 million. 26 April 2024
Pharmaceutical
Australian medicines regulator the Therapeutic Goods Administration (TGA) has published updated acceptable intake (AI) information for nitrosamine impurities in medicines consistent with recent EMA updated information- external site. 26 April 2024
Biotechnology
German pharma and life science company Merck KGaA today revealed it is investing more than 300 million euros ($320 million) in a new research center at its global headquarters in Darmstadt, Germany. 25 April 2024
Pharmaceutical
With peptides, oligos and peptide conjugates continuing to attract drug developer interest and industry capacity in short supply, China’s WuXi AppTec says its Changzhou site has been approved by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). 19 April 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) for intravenous (IV) infusion has been launched in Japan. 17 April 2024
Biotechnology
UK pharma major GSK says that the US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for its 5-in-1 meningococcal ABCWY (MenABCWY) vaccine candidate. 16 April 2024
Pharmaceutical
Japanese pharma major Shionogi has received approval of a supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil) for the treatment and post-exposure prophylaxis for influenza virus infection for pediatrics aged 5 to 15 April 2024
Biotechnology
The UK subsidiary of Japanese pharma major Takeda has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) for lanadelumab (trademarked Takhzyro) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged two years to less than 12. 11 April 2024
Biotechnology
UK pharma major AstraZeneca today revealed that Fasenra (benralizumab) is now approved by the US Food and Drug Administration (FDA) for add-on maintenance treatment for patients with severe asthma aged six to 11 with an eosinophilic phenotype. 11 April 2024
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved the medicine Nulibry (fosdenopterin) to treat the genetic disease Molybdenum Cofactor Deficiency (MoCD) Type A. 9 April 2024
Pharmaceutical
French pharma major Sanofi today announced the UK launch of Verorab (Sanofi Inactivated Rabies Vaccine) an inactivated rabies vaccine indicated for pre-exposure and post-exposure prophylaxis of rabies in all age groups. 5 April 2024
Pharmaceutical
Japan’s Asahi Kasei Pharma has concluded an agreement with Swedish Orphan Biovitrum Japan Co regarding exclusive distribution rights in Japan for the additional indication of idiopathic thrombocytopenic purpura (immune thrombocytopenia) for Doptelet (avatrombopag maleate), a thrombopoietin receptor agonist. 2 April 2024
Pharmaceutical
Earlier this week Merck & Co gained much awaited approval from the Food and Drug Administration for its pulmonary arterial hypertension (PAH) treatment Winrevair (sotatercept-csrk) injection. 30 March 2024
Pharmaceutical
Germany’s Merck KGaA says it has expanded its M Lab Collaboration Center in Shanghai, the company’s largest in its global network of 10 interconnected labs. 29 March 2024
Pharmaceutical
Eisai today announced that it has entered into an agreement to divest its Japanese rights for vertigo and equilibrium disturbance treatment Merislon (betahistine mesilate) and muscle relaxant Myonal (eperisone hydrochloride) to fellow Japan based Kaken Pharmaceutical. 29 March 2024
Pharmaceutical
In Latin America, the average percentage of the public budget for health is 12.75%, half of what is allocated by the 38 countries that make up the Organization for Economic Cooperation and Development (OECD), which on average is 24.5%. 6 June 2025
Pharmaceutical
US cardiorenal-focussed drugmaker Ardelyx announced that Mike Kelliher, formerly executive vice president, corporate development and strategy, has been promoted to chief business officer, and James Brady has joined the company as chief human resources officer. 6 June 2025
Biotechnology
Sweden’s Sobi and US biopharma Apellis Pharmaceuticals have presented new data from the open-label period of the Phase III VALIANT study, investigating Aspaveli/Empaveli (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). 6 June 2025
Biotechnology
Japan’s Otsuka today presented positive results from a pre-specified interim analysis of the Phase III VISIONARY study (NCT05248646) evaluating sibeprenlimab, for the treatment of immunoglobulin A nephropathy (IgAN) in adults. 6 June 2025
Biotechnology
China-based Kelun-Biotech Biopharmaceutical announced the placement of 5,918,000 H shares under its general mandate, representing approximately 2.54% of the enlarged share capital of the company post the placement. The shares were placed at HK$331.8 per share, raising net proceeds of around US$250 million. 6 June 2025
Biotechnology
The dynamics of the Friedreich's ataxia market are anticipated to change as companies across the globe work towards the development of new drug therapy options to treat this disease, according to a report from DelveInsight. 6 June 2025
Biotechnology
Texas-based ImmunoPrecise Antibodies, a leader in AI-driven biotherapeutics, closed 22% higher Thursday. 6 June 2025
Pharmaceutical
US biotech Trevi Therapeutics has raised around $115 million in a public stock offering, giving it fresh momentum to continue developing its investigational therapy Haduvio (nalbuphine) for chronic cough. 6 June 2025
Biotechnology
Genetic testing company 23andMe is preparing for a renewed auction of its assets after a federal judge agreed to reopen the sale process, following an eleventh hour bid from company co-founder Anne Wojcicki. 6 June 2025
Pharmaceutical
AstraZeneca has received European approval for a fixed-duration regimen of Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, for adults newly diagnosed with chronic lymphocytic leukemia (CLL). 6 June 2025
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the use of German pharma major Bayer’s Nubeqa (darolutamide) for the treatment of adult patients with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT). 6 June 2025
Biotechnology
US commercial-stage drugmaker Corcept Therapeutics has presented results from its DAZALS study of dazucorilant in patients with amyotrophic lateral sclerosis (ALS) at the European Network to Cure ALS (ENCALS) 2025 annual meeting. 6 June 2025
Biotechnology
US gene therapy company RegeNXBio yesterday announced new positive interim data from the Phase I/II AFFINITY DUCHENNE trial. Updates include positive functional, safety and biomarker data for RGX-202, RegeNXBio’s potential best-in-class, investigational gene therapy for Duchenne muscular dystrophy. 6 June 2025
Biotechnology
The New Drug Application (NDA) for the combination of fruquintinib and sintilimab for locally advanced or metastatic renal cell carcinoma patients who have failed prior treatment with one tyrosine kinase inhibitor (TKI) has been accepted for review by the China National Medical Products Administration (NMPA). 5 June 2025
Biotechnology
San Jose, USA-based biotech Allay Therapeutics today announced the completion of a $57.5 million Series D financing round with leading global investors. 5 June 2025
Biotechnology
German genetic medicine company ViGeneron has announced a rebrand to become VeonGen Therapeutics. 5 June 2025
Biotechnology
US rare disease meds developer Sarepta Therapeutics revealed that its rAAVrh74 viral vector used in the investigational gene therapy SRP-9003 (bidridistrogene xeboparvovec) for the treatment of limb-girdle muscular dystrophy type 2E/R4, has been granted platform technology designation by the US Food and Drug Administration. 5 June 2025
Biotechnology
AI-enabled biotech Juvenescence today announced the acquisition of Ro5 Inc, a proprietary AI drug discovery company. 5 June 2025
Biotechnology
US biopharma Cullinan Therapeutics has entered into an agreement with Genrix Bio for an all-indication, exclusive license to velinotamig, a BCMAxCD3 bispecific T-cell engager for everywhere outside Greater China. 5 June 2025
Pharmaceutical
China’s National Medical Products Administration approved its first domestically-developed nine-valent human papillomavirus (HPV) vaccine on Thursday. 5 June 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze